Tibet Weixinkang Pharmaceutical announced that its wholly-owned subsidiary Baiyi Pharmaceutical's pediatric multi-vitamins injection will be renewed into the "National Medical Insurance Catalog" during the agreement period. This pharmaceutical is an exclusive variety, suitable for preventing vitamin deficiency in patients under 11 years old receiving parenteral nutrition. Sales revenue reached 45.507 million yuan in 2023, accounting for 3.44% of the company's current revenue; in the first three quarters of 2024, sales revenue reached 52.4323 million yuan, accounting for 5.27% of the company's current revenue. The inclusion in the medical insurance catalog this time will benefit the market promotion and sales of the product, further consolidating the company's market position in the field of intravenous vitamin supplements.
卫信康:小儿多种维生素注射液续约纳入国家医保目录
Tibet Weixinkang Pharmaceutical: Pediatric multi-vitamins injection renewed into the national medical insurance catalog.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.